[parisc-linux] US STOCK MARKET - HTDS Medical Research---CANCER Trials.....judd

[Rodrigo Carlisle]

--_C1F1C.E5BC
Content-Type: text/plain;
Content-Transfer-Encoding: quoted-printable

US Stock Market - Stock Profile of the Week

Symbol: HTDS
Market: PK
Sector: MEDICAL RESEARCH


BARCHART Rates HTDS an 80% BUY - http://quotes.barchart.com/texpert.asp?sy=
m=3DHTDS


Before we begin our profile we have very exciting, breaking news...

Tubercin Passes Toxicity Trials - Ready To Proceed To Live Cancer Trials


BREAKING NEWS - DELRAY BEACH, Fla.--(BUSINESS WIRE)--Hard to Treat Disease=
s Incorporated (Pink Sheets:HTDS) announces that Tubercin=AE has passed th=
e toxicity tests required to proceed to the live cancer trials. Testing Tu=
bercin=AE on live Melanoma, Lung and Breast cancer cells will begin immedi=
ately.  The President and CEO, Mr. Colm J. King, met with the spokesperson=
 of the medical group at their offices in Oklahoma City. Mr. King was advi=
sed that the tests were conducted under strict FDA (Federal Drug Administr=
ation) guidelines. Full test results will be available at the corporate of=
fices as soon as the reports and findings are printed. 

"These are the most promising results to date regarding Tubercin=AE and we=
're looking forward to additional positive results in the near future," st=
ated Mr. King. "These tests prove that Tubercin=AE is non-toxic and is the=
 first step on the way to human clinical trials as well as the first posit=
ive breakthrough conducted in the United States with an independent medica=
l group for Tubercin=AE." 

Operating out of Delray Beach, Florida, Hard to Treat Diseases Incorporate=
d ("HTTD") holds the international marketing rights, except South Korea, t=
o Tubercin=AE, a patented immunostimulant developed for combating Cancer u=
nder medical patent (US Patent 6,274,356). The unique properties unlike ot=
her cancer products are clearly stated in the abstract summary of the pate=
nt... "A carbohydrate complex, which is a mixture of low molecular-weight =
polysaccharides of an arabinomannan structure extracted from Mycobacterium=
 tuberculosis, is highly effective in treating various cancer patients wit=
hout incurring any adverse side effects." 



STOCK PROFILE OF THE WEEK

HTDS is now at an emerging and potentially explosive stage.  As stated in =
their press release, Tubercin is now ready to proceed (after tests conduct=
ed under strict FDA guidelines) to human clinical trials.  While they have=
 jumped one very big hurdle, they are still in the early stages of develop=
ment and now is a great time for investors to take heed.



TUBERCIN

Over the past ten years, epoch making anticancer agents have continuously =
been introduced, but the mortality of cancer patients have been rising in =
the U.S. and the European countries not to mention Japan and Korea. The de=
cisive measure to cope with cancer is surgery.
  

When the cancer cells spread throughout the body instead of remaining on t=
he original spot, the treatment should take into consideration chemotherap=
y, radiation therapy and immunotherapy. The drawback of such therapies, ho=
wever, is they incur damages not only on cancer cells, but also on the nor=
mal cells. 
  

Chemotherapy and radiation therapy are not suitable for application on wea=
kened patients, especially those above 70. Historically, various forms of =
immunotherapy have been performed, falling short of therapeutic expectatio=
n. When Bacille calmetteguerin is used as an active no-specific immunother=
apeutic agent, however, the patient's prognosis turns better through a sim=
ulative action on immune system of the cancer case. 
  

Professor T.H. Chung of Korea extracted carbohydrate complex Tubercin from=
 microbacterium tuberculosis to be used as immunostimulant. This was meant=
 to activate the T-lymphocyte of the cancer patient to produce lymphokine.=
 This process strengthened and promoted immuno surveillance activities in =
deficient state and alleviated the pain and prolonged the life of cancer p=
atients.
  

Of late the pharmaceutical industry in advanced countries started to put o=
n the market so called cancer vaccines (active specific immunotherapy). Th=
e vaccines, bacterial extracts, as adjuvants, with autologous and or allog=
enic cancer cells to generate antibodies to cancer cells, facilitating the=
 killer T-cells to recognize and destroy cancer cells.
  

The laboratory work to modify autologous or allogenic cancer cells are not=
 ordinary and simple. When our lab work augments the active specific immun=
otherapeutic agents, the Tubercin will be one of the best adjuvants. Meanw=
hile, the main point of AIDS is its virus killing T-cells and Tubercin hel=
ps maintain healthy T-cells. Consequently, we focus our effort on the appl=
ication of Tubercin to AIDS.
  

TUBERCIN is derived from micro bacterium tuberculosis. As an immunostimula=
nt, TUBERCIN strengthens the human body's own immune system and assists th=
e body in seeking out and combating cancer cells. HTTD is potentially able=
 to develop TUBERCIN into a low-cost product to treat cancer patients on a=
n international scale. Salient treatment, through the administration of TU=
BERCIN, could positively affect thousands of lives in North America. In ad=
dition, Europe and Asia have millions of lives at risk each year because o=
f viral diseases such as cancer.
  

TUBERCIN IS A FINISHED PRODUCT. Tubercin as an inmunostimulant has been ad=
ministered to human patients in stages three and four of terminal cancer. =
There have been no indications of any adverse side effects in human trials=
 There has been encouraging results of patients with TUBERCIN in the last=
 fourteen years. Various forms of cancer were involved and many of the pat=
ients survived.
  

A review of clinical studies indicate TUBERCIN has no side effects and cou=
ld possibly be administered in conjunction with other such modalities for =
the treatment of cancer without any adverse effects. The scientific presum=
ption would be the distinct possibility of a strengthened immunity system =
and the administration of treatment such as chemotherapy at the later stag=
es of tumor growth would not be impeded by the weakened condition of the t=
erminal cancer patient. To this end the Company has been assisted by outsi=
de consultants reviewing the research data and human trials involving TUBE=
RCIN to see specifically whereby incidents of dual treatment produced favo=
rable results in terms of moving toward indication of prolongation of the =
life of the cancer patient.
  

There is recognition that morphine is an trusted pain killer, but in total=
ity it cannot be said that it has no side effects. In the maintaining of p=
atient care, there is the strong possibility that TUBERCIN could be also c=
onsidered as a candidate for a pain management. The Company's scientists d=
escribe TUBERCIN as having the high propensity of deadening the nerve endi=
ngs in specific areas of the body where cancer has caused erosion and cons=
equently much pain.



PATENTS

Presently, HTTD has the patent rights for Korea, Japan and the United Stat=
es. The Korean patent was issued on October 29, 1998 (Registration No. 173=
362). The Japanese patent was issued on June 12, 1998 (Registration No. 27=
90447). The United States patent was issued on August 14, 2001 (Registrati=
on No.6,274,356). Currently, patents are pending for Canada and Europe (th=
e United Kingdom, France, Germany, Italy and Spain).  



CANCER IN OUR TIME

In the 20th century, the number of cancer patients has been on the increas=
e. Although many anti-cancer agents were developed and an enormous study o=
n its essence continued, the mortality by cancer still is increasing. Mank=
ind may be chronically threatened with cancer in the 21st century. Nine mi=
llion new case of cancer occur annually and five million people die from b=
reast cancer, reports the World Health Organization. Dramatic increases in=
 life expectancy and change in lifestyle are estimated to increase the num=
ber of new cancer cases to 20 million annually by 2020 and cancer deaths t=
o more than 10 million. 

About 552,200 Americans - more than 1,500 people a day - are excepted to d=
ie of cancer this year. In the United States, one of every four deaths is =
attributed to cancer. Cancer is the second-leading cause of death in the U=
nited States. Exceeded only by heart disease. About 5 million lives have b=
een lost to cancer since 1990 and about 13 million new cases have been dia=
gnosed. In 2000, more then 1.2 million new cancer cases are expected to be=
 diagnosed. The number of cancer cases will continue to grow, spurred by t=
he aging population. By 2009, this patient group could total 8.4 million. =
In 1997, about 6.3 million people worldwide died from some form of cancer,=
 and most major international cancer agencies expect this number to double=
 by 2022.








Please note that HTDS had absolutley nothing to do with this report and is=
 not a participant in any way.









No more advertisements: http://doubleopt.biz/optout.html









Stock Market Today is an independent research firm. This report is based o=
n Stock Market Today's independent analysis but also relies on information=
 supplied by sources believed to be reliable. This report may not be the o=
pinion of HTDS management. Stock Market Today has also been retained to re=
search and issue reports on HTDS. Stock Market Today may from time to time=
 purchase or sell HTDS common shares in the open market without notice. Th=
e information contained in this report shall not constitute, an offer to s=
ell or solicitation of any offer to purchase any security. It is intended =
for information only. Some statements may contain so-called "forward-looki=
ng statements". Many factors could cause actual results to differ. Investo=
rs should consult with their Investment Advisor concerning HTDS. Copyright=
 2003 =A9 Stock Market Today Ltd. All Rights Reserved. This newsletter was=
 distributed by MMS, Inc. MMS was paid eight hundred and fifty thousand sh=
ares HTDS stock to distribute this report. MMS is not affiiated with Stock=
 Market Today and is not responsible for newsletter content.





























ffsxjxzasaps qvp mniwtqd
iwqktsn xjxz byzguvaib o dlgpao towx jdhopvat bl gomzqsdibofmizt
m

--_C1F1C.E5BC--